Literature DB >> 16378158

Primary hyperparathyroidism in multiple endocrine neoplasia type 1: individualized management with low recurrence rates.

Chen-Hsen Lee1, Ling-Ming Tseng, Jui-Yu Chen, Hsin-Yun Hsiao, An-Hang Yang.   

Abstract

BACKGROUND: To evaluate the outcomes in different surgical modalities for primary hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN1) patients, intraoperative findings from a single surgeon were studied to investigate a potentially improved modality of parathyroidectomy (PTx).
METHODS: All 22 patients had PTx by a single surgeon in the past 21 years. Three modalities of PTx were used, depending on the operative findings, after all parathyroids and the thymus were identified. If fewer than three glands were enlarged, selective removal of the enlarged glands with or without biopsy of a normal-appearing gland was performed (selective PTx); if all glands were enlarged, either a subtotal PTx leaving a 50-mg remnant in situ or a total PTx with autotransplantation (TPTx + AT) was performed.
RESULTS: There were 7 men and 15 women, aged 22 to 67 years (average, 43 years). Sixteen had familial and six had sporadic MEN1. They underwent 23 operations, including 11 selective PTx, 6 subtotal PTx, and 6 TPTx + AT. On follow-up for 1 to 19 years, only one patient (4.6%) had recurrent hyperparathyroidism 5.5 years after subtotal PTx. Others had either normocalcemia (n = 14; 63.6%) or hypocalcemia (n = 7; 31.8%). Those who had either a subtotal PTx or TPTx + AT had a significantly higher rate of postoperative hypocalcemia than those who had a selective PTx (9.9% vs. 54.5%; P = .032; Fisher's exact test).
CONCLUSIONS: Primary hyperparathyroidism in our MEN1 patients was less aggressive than that reported in the literature. Selective PTx according to the intraoperative findings achieved optimal outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16378158     DOI: 10.1245/ASO.2006.12.009

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Impact of "Tailored" Parathyroidectomy for Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1.

Authors:  Kiyomi Horiuchi; Momoko Sakurai; Kento Haniu; Erin Nagai; Hiroki Tokumitsu; Yusaku Yoshida; Yoko Omi; Akiko Sakamoto; Takahiro Okamoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

2.  Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.

Authors:  Maria D Balsalobre Salmeron; Jose Manuel Rodriguez Gonzalez; Joan Sancho Insenser; Joan Sancho Fornos; Albert Goday; Nuria Maria Torregrosa Perez; Antonio Rios Zambudio; Pascual Parrilla Paricio; Antonio Sitges Serra
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 3.  The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.

Authors:  Jennifer M J Schreinemakers; Carolina R C Pieterman; Anouk Scholten; Menno R Vriens; Gerlof D Valk; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 4.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

Review 5.  Bilateral neck exploration in primary hyperparathyroidism--when is it selected and how is it performed?

Authors:  Jacob Moalem; Marlon Guerrero; Electron Kebebew
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

6.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

Review 7.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

8.  Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up.

Authors:  Bas A Twigt; Anouk Scholten; Gerlof D Valk; Inne H M Borel Rinkes; Menno R Vriens
Journal:  Orphanet J Rare Dis       Date:  2013-04-01       Impact factor: 4.123

9.  Surgical approach to the patient with familial hyperparathyroidism.

Authors:  Lindi H VanderWalde; Philip I Haigh
Journal:  Curr Treat Options Oncol       Date:  2006-07

10.  Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?

Authors:  Enrico Erdas; Nicola Aste; Luca Pilloni; Angelo Nicolosi; Sergio Licheri; Antonello Cappai; Marco Mastinu; Filomena Cetani; Elena Pardi; Stefano Mariotti; Mariano Pomata
Journal:  BMC Cancer       Date:  2012-12-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.